Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein

被引:92
作者
Hochman, JH [1 ]
Yamazaki, M [1 ]
Ohe, T [1 ]
Lin, JH [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.2174/1389200023337559
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The pharmacological effects of a drug are highly dependent on the absorption, metabolism, elimination, and distribution of the drug. In the past few years it has become apparent that transport proteins play a major role in regulating the distribution, elimination and metabolism of some drugs. As a consequence of our new understanding of the influence of transport proteins on the pharmacokinetic and pharmacodynamic behavior of drugs, increasing attention has been focused on the potential for drug-drug interactions arising from interactions with drug transport proteins. The efflux transporter P-glycoprotein (P-gp) has received the most attention with regard to its role in restricting drug absorption and distribution and as a potential source for variability in drug pharmacokinetics and pharmacodynamics. This review will focus on the evaluation of drug candidates to assess the potential for drug interactions at the level of P-gp. We will discuss the role of P-gp in drug disposition, the biochemistry of P-gp efflux as it relates to model systems to study drug interactions with P-gp, and the implementation of P-gp assay models within the drug discovery process.
引用
收藏
页码:257 / 273
页数:17
相关论文
共 50 条
[31]   STATISTICAL ANALYSIS TO COMPARE VARIOUS IN VITRO CRITERIA FOR PREDICTING P-GLYCOPROTEIN TRANSPORTER MEDIATED DRUG-DRUG INTERACTIONS IN VIVO [J].
Arya, V. ;
Zhou, T. ;
Yang, X. ;
Vaidyanathan, J. ;
Zhang, L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) :S21-S21
[32]   P-Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer [J].
Mealey, K. L. ;
Fidel, J. .
JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (01) :1-6
[33]   Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein [J].
Zahir, Hamim ;
Kobayashi, Fumiaki ;
Zamora, Cynthia ;
Gajee, Roohi ;
Gordon, Michael S. ;
Babiker, Hani M. ;
Wang, Qiang ;
Greenberg, Jonathan ;
Wagner, Andrew J. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03) :298-306
[34]   Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib [J].
Yamamiya, Ikuo ;
Hunt, Allen ;
Takenaka, Toru ;
Sonnichsen, Daryl ;
Mina, Mark ;
He, Yaohua ;
Benhadji, Karim A. ;
Gao, Ling .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (10) :966-978
[35]   Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein [J].
Lu, Jian ;
Zhang, Yuanjin ;
Sun, Min ;
Liu, Mingyao ;
Wang, Xin .
PHYTOMEDICINE, 2017, 26 :1-10
[36]   Assessment of the potential drug-drug interaction between carvedilol and clopidogrel mediated through intestinal P-glycoprotein [J].
Incecayir, T. ;
Ilbasmis-Tamer, S. ;
Tirnaksiz, F. ;
Degim, T. .
PHARMAZIE, 2016, 71 (08) :472-477
[37]   Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein [J].
Yamazaki, Shinji ;
Loi, Cho-Ming ;
Kimoto, Emi ;
Costales, Chester ;
Varma, Manthena V. .
DRUG METABOLISM AND DISPOSITION, 2018, 46 (08) :1200-1211
[38]   P-GLYCOPROTEIN TRANSPORTER IN DRUG DEVELOPMENT [J].
Prachayasittikul, Veda ;
Prachayasittikul, Virapong .
EXCLI JOURNAL, 2016, 15 :113-118
[39]   Posaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoprotein [J].
Shumaker, Abby C. ;
Bullard, Heather M. ;
Churpek, Jane ;
Knoebel, Randall W. .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) :1758-1761
[40]   POSACONAZOLE-DIGOXIN DRUG-DRUG INTERACTION MEDIATED BY INHIBITION OF P-GLYCOPROTEIN [J].
Dunker, Abby ;
Bullard, Heather ;
Churpek, Jane ;
Knoebel, Randall .
CRITICAL CARE MEDICINE, 2016, 44 (12)